GameChangers |  CEimpact

Irritable bowel syndrome is a common disorder that exacts a significant toll on quality of life. For the first time, the American College of Gastroenterology has published guidelines on the diagnosis and treatment for this disorder. This episode is accredited for CPE. Subscribe at CEimpact ( https://www.ceimpact.com/pharmacist ) and claim your CE today! Reference: Lacy, Brian E. PhD, MD, FACG1; Pimentel, Mark MD, FACG2; Brenner, Darren M. MD, FACG3; Chey, William D. MD, FACG4; Keefer, Laurie A. PhD5; Long, Millie D. MDMPH, FACG (GRADE Methodologist)6; Moshiree, Baha MD, MSc, FACG7 ACG Clinical Guideline: Management of Irritable Bowel Syndrome, The American Journal of Gastroenterology: January 2021 - Volume 116 - Issue 1 - p 17-44 doi: 10.14309/ajg.0000000000001036. Accessed at https://journals.lww.com/ajg/Fulltext/2021/01000/ACG_Clinical_Guideline__Management_of_Irritable.11.aspx Bristol stool scale (recommend tertiary references): Lewis, SJ; Heaton, KW (September 1997). "Stool form scale as a useful guide to intestinal transit time". Scand. J. Gastroenterol. 32 (9): 920–4. doi:10.3109/00365529709011203. PMID 9299672. CPE details for GameChangers Podcast February 2021 Learning Objective: Discuss appropriate treatments for irritable bowel syndrome 0107-0000-21-083-H01-P 0.2 CEU/2.0 Hrs (Knowledge) Initial Release Date: 02/23/21 Expiration Date: 02/23/24 Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Atopic Dermatitis is not extensively taught in pharmacy curriculum. With several international medical societies publishing updated guidelines and newly approved medications, it's time for a review. Clinicians can learn ways to help treat patients under the skin. This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today! The CE for this episode is supported by an educational grant from Xellia Pharmaceuticals, a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. See omnystudio.com/listener for privacy information.

Learn more about your ad choices. Visit megaphone.fm/adchoices

It's the GameChangers' Birthday! This episode is a rapid review of a few subjects to celebrate the first year of GameChangers. From oral iron administration to the use of metronidazole with alcohol or serotonin syndrome, this episode has all the ingredients for a celebration! GameChangers' host, Geoff Wall, just released new music! Check out his latest EP here: https://open.spotify.com/artist/0J26ngHZz2cf6mQR3UiEHW?827= or wherever you listen to music! Reference: Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017 Nov;4(11):e524-e533. doi: 10.1016/S2352-3026(17)30182-5. Epub 2017 Oct 9. PMID: 29032957. Kaundal R, Bhatia P, Jain A, et al. Randomized controlled trial of twice-daily versus alternate-day oral iron therapy in the treatment of iron-deficiency anemia. Ann Hematol. 2020 Jan;99(1):57-63. doi: 10.1007/s00277-019-03871-z. Epub 2019 Dec 6. PMID: 31811360. Visapää JP, Tillonen JS, Kaihovaara PS, et al. Lack of disulfiram-like reaction with metronidazole and ethanol. Ann Pharmacother. 2002 Jun;36(6):971-4. doi: 10.1345/aph.1A066. PMID: 12022894. Orlova Y, Rizzoli P, Loder E. Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome. JAMA Neurol. 2018 May 1;75(5):566-572. doi: 10.1001/jamaneurol.2017.5144. PMID: 29482205; PMCID: PMC5885255. CPE details for GameChangers Podcast April 2021 Learning Objective: Discuss the evidence-based dosing of oral iron supplementation. 0107-0000-21-158-H01-P 0.2 CEU/2 Hrs (Knowledge) Initial Release Date: 04/06/21 Expiration Date: 03/02/24 Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Aspirgillosis is a deadly fungal infection that is a major cause of mortality in patients with impaired immune systems. The current standard of care has been voriconazole due to the favorable side effect profile compared to amphotericin. However, posaconazole may not have there adverse effects and be a reasonable course of therapy. Is voriconazole just just a phase? Today's episode is sponsored by a special CEimpact FREE Law focused webinar: Save your spot - FREE LIVE LAW CE webinar on April 1st. SPOTS ARE LIMITED! https://ceimpact.com/law Reference: Maertens JA, Rahav G, Lee DG, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021 Feb 6;397(10273):499-509. doi: 10.1016/S0140- 6736(21)00219-1. PMID: 33549194. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America, Clinical Infectious Diseases, Volume 63, Issue 4, 15 August 2016, Pages e1–e60, hMps://doi.org/10.1093/cid/ciw326 CPE details for GameChangers Podcast March 2021 Learning Objective: Develop appropriate treatment of aspergillosis infections based on clinical studies. 0107-0000-21-097-H01-P 0.25 CEU/2.5 Hrs (Knowledge) Initial Release Date: 03/02/21 Expiration Date: 03/02/24 Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Learn more about your ad choices. Visit megaphone.fm/adchoices